A Novel Y-Shaped, S-O-N-O-S-Bridged Cross-Link between Three Residues C22, C44, and K61 Is Frequently Observed in the SARS-CoV-2 Main Protease

ACS Chem Biol. 2023 Mar 17;18(3):449-455. doi: 10.1021/acschembio.2c00695. Epub 2023 Jan 11.

Abstract

As the COVID-19 pathogen, SARS-CoV-2 relies on its main protease (MPro) for pathogenesis and replication. During crystallographic analyses of MPro crystals that were exposed to the air, a uniquely Y-shaped, S-O-N-O-S-bridged post-translational cross-link that connects three residues C22, C44, and K61 at their side chains was frequently observed. As a novel covalent modification, this cross-link serves potentially as a redox switch to regulate the catalytic activity of MPro, a demonstrated drug target of COVID-19. The formation of this linkage leads to a much more open active site that can potentially be targeted for the development of novel SARS-CoV-2 antivirals. The structural rearrangement of MPro by this cross-link indicates that small molecules that lock MPro in the cross-linked form can potentially be used with other active-site-targeting molecules such as paxlovid for synergistic effects in inhibiting SARS-CoV-2 viral replication.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Antiviral Agents / chemistry
  • Antiviral Agents / pharmacology
  • COVID-19*
  • Humans
  • Molecular Docking Simulation
  • Protease Inhibitors / chemistry
  • SARS-CoV-2
  • Viral Nonstructural Proteins / chemistry

Substances

  • nirmatrelvir and ritonavir drug combination
  • 3C-like proteinase, SARS-CoV-2
  • Viral Nonstructural Proteins
  • Antiviral Agents
  • Protease Inhibitors